T-Rapa6 and T-Rapa12 Cells Differentially Mediate Acute Gvhd after Low-Intensity Allogeneic HCT
Year: 2014
Type: article
Abstract: In a phase II clinical trial, pre-emptive DLI using rapamycin-resistant donor CD4+ T cells manufactured in 12-days (T-Rapa12 cells) was associated with conversion of mixed chimerism, GVL effects in patients with refractory hematologic malignancy, and a moderate rate and severity of GVHD (Blood, 2013). We recently found that culture interval truncation to 6-days yielded T-Rapa6 cells with a unique gene expression profile (∼6% of genes differentially expressed relative to T-Rapa12 cells; Cytotherapy, 2013).
Authors: David Halverson, Scott Rowley, Brenna Hansen, Bazetta Blacklock Schuver, Miriam Mossoba, Seth Steinberg, Fran Hakim, Roger Kurlander, Juan Gea-Banacloche, Claude Sportes, Nancy Hardy, Dennis Hickstein, Steven Z. Pavletic, Hanh Khuu, Luciano Castiello, Marianna Sabatino, David F. Stroncek, Bruce Levine, Carl H. June, Michele L. Donato, Andre Goy, Robert Korngold, Andrew Pecora, Michael R. Bishop, Ronald Gress, Daniel Fowler
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2321724392